Repurposing CRISPR/Cas9 for in situ functional assays

Genes and Development

Volumn 27, Issue 23, 2013, Pages 2602-2614

  Malina, Abba ^a   Mills, John R ^a,d   Cencic, Regina ^a   Yan, Yifei ^b   Fraser, James ^a   Schippers, Laura M ^a   Paquet, Marilène ^b   Dostie, Josée ^a   Pelletier, Jerry ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MAYO CLINIC   (United States)

Author keywords

Cas9; CRISPR; Functional screening; Genome editing; p53

Indexed keywords

CRISPR ASSOCIATED 9; GREEN FLUORESCENT PROTEIN; GUIDE RNA; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CODON; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; FLUORESCENCE ANALYSIS; GENE; GENE DISRUPTION; GENE LOCUS; GENE TARGETING; GENETIC ENGINEERING; GENETIC SELECTION; HETEROLOGOUS EXPRESSION; LYMPHOMA; METHODOLOGY; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TRP53 GENE;

MAMMALIA;

EID: 84888781186     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.227132.113     Document Type: Article

References (54)

1. Bassett AR, Tibbit C, Ponting CP, Liu JL. 2013. Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. Cell Rep 4: 220-228.
2. Certo MT, Ryu BY, Annis JE, Garibov M, Jarjour J, Rawlings DJ, Scharenberg AM. 2011. Tracking genome engineering outcome at individual DNA breakpoints. Nat Methods 8: 671-676.
3. Chang K, Elledge SJ, Hannon GJ. 2006. Lessons from nature: MicroRNA-based shRNA libraries. Nat Methods 3: 707-714.
4. Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, Xiong JW, Xi JJ. 2013. Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res 23: 465-472.
5. Cho SW, Kim S, Kim JM, Kim JS. 2013. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31: 230-232.
6. Chylinski K, Le Rhun A, Charpentier E. 2013. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol 10: 726-737.
7. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823.
8. Cradick TJ, Fine EJ, Antico CJ, Bao G. 2013. CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res 41: 9584-9592.
9. DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM. 2013. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Res 41: 4336-4343.
10. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 37: 1289-1295.
11. Dickinson DJ, Ward JD, Reiner DJ, Goldstein B. 2013. Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination. Nat Methods 10: 1028-1034.
12. Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan CA, Musunuru K. 2013. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12: 393-394.
13. Dow LE, Lowe SW. 2012. Life in the fast lane: Mammalian disease models in the genomics era. Cell 148: 1099-1109.
14. Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, Sundstrom M, Micke P, Botling J, Soussi T. 2012. Datadriven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci 109: 9551-9556.
15. Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz D, Vassilev LT, Serrano M. 2007. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res 67: 7350-7357.
16. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658-2669.
17. Feng Z, Zhang B, Ding W, Liu X, Yang DL, Wei P, Cao F, Zhu S, Zhang F, Mao Y, et al. 2013. Efficient genome editing in plants using a CRISPR/Cas system. Cell Res 23: 1229-1232.
18. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al. 2011. COSMIC: Mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39: D945-D950.
19. Friedland AE, Tzur YB, Esvelt KM, Colaiacovo MP, Church GM, Calarco JA. 2013. Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat Methods 10: 741-743.
20. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD. 2013. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31: 822-826.
21. Gaj T, Gersbach CA, Barbas CF III. 2013. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31: 397-405.
22. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, et al. 2013. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154: 442-451.
23. Gratz SJ, Cummings AM, Nguyen JN, Hamm DC, Donohue LK, Harrison MM, Wildonger J, O'Connor-Giles KM. 2013. Genome engineering of Drosophila with the CRISPR RNAguided Cas9 nuclease. Genetics 194: 1029-1035.
24. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, et al. 2013. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31: 827-832.
25. Hwang WY, Fu Y, Reyon D, Maeder ML, Kaini P, Sander JD, Joung JK, Peterson RT, Yeh JR. 2013a. Heritable and precise zebrafish genome editing using a CRISPR-Cas system. PLoS ONE 8: e68708.
26. Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK. 2013b. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 31: 227-229.
27. Jao LE, Wente SR, Chen W. 2013. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. Proc Natl Acad Sci 110: 13904-13909.
28. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. 2013a. RNAguided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31: 233-239.
29. Jiang W, Zhou H, Bi H, Fromm M, Yang B, Weeks DP. 2013b. Demonstration of CRISPR/Cas9/sgRNA-mediated targeted gene modification in Arabidopsis, tobacco, sorghum and rice. Nucleic Acids Res doi: 10.1093/nar/gkt780.
30. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816-821.
31. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. 2013. RNAprogrammed genome editing in human cells. Elife 2: e00471.
32. Katic I, Grosshans H. 2013. Targeted heritable mutation and gene conversion by Cas9-CRISPR in Caenorhabditis elegans. Genetics doi: 10.1534/genetics.113.155754.
33. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. 2007. Tumor growth need not be driven by rare cancer stem cells. Science 317: 337.
34. Li JF, Norville JE, Aach J, McCormack M, Zhang D, Bush J, Church GM, Sheen J. 2013a. Multiplex and homologous recombination-mediated genome editing in Arabidopsis and Nicotiana benthamiana using guide RNA and Cas9. Nat Biotechnol 31: 688-691.
35. Li W, Teng F, Li T, Zhou Q. 2013b. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol 31: 684-686.
36. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, Eichtinger M, Jiang T, Foley JE, Winfrey RJ, Townsend JA, et al. 2008. Rapid 'open-source' engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 31: 294-301.
37. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. 2013. RNA-guided human genome engineering via Cas9. Science 339: 823-826.
38. Miao J, Guo D, Zhang J, Huang Q, Qin G, Zhang X, Wan J, Gu H, Qu LJ. 2013. Targeted mutagenesis in rice using CRISPR-Cas system. Cell Res 23: 1233-1236.
39. Muller PA, Vousden KH. 2013. p53 mutations in cancer. Nat Cell Biol 15: 2-8.
40. Nekrasov V, Staskawicz B, Weigel D, Jones JD, Kamoun S. 2013. Targeted mutagenesis in the model plant Nicotiana benthamiana using Cas9 RNA-guided endonuclease. Nat Biotechnol 31: 691-693.
41. Oren M, Rotter V. 2010. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2: a001107.
42. Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR. 2013. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 31: 839-843.
43. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
44. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. 2013. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152: 1173-1183.
45. Ramsby M, Makowski G. 2011. Differential detergent fractionation of eukaryotic cells. Cold Spring Harb Protoc 2011: prot5592.
46. Sapranauskas R, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V. 2011. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res 39: 9275-9282.
47. Semenova E, Jore MM, Datsenko KA, Semenova A, Westra ER, Wanner B, van der Oost J, Brouns SJ, Severinov K. 2011. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc Natl Acad Sci 108: 10098-10103.
48. Shan Q, Wang Y, Li J, Zhang Y, Chen K, Liang Z, Zhang K, Liu J, Xi JJ, Qiu JL, et al. 2013. Targeted genome modification of crop plants using a CRISPR-Cas system. Nat Biotechnol 31: 686-688.
49. Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, Zhang X, Zhang P, Huang X. 2013. Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res 23: 720-723.
50. Sorek R, Lawrence CM, Wiedenheft B. 2013. CRISPR-mediated adaptive immune systems in bacteria and archaea. Annu Rev Biochem 82: 237-266.
51. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, et al. 2006. Smallmolecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci 103: 1888-1893.
52. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R. 2013. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153: 910-918.
53. Weber K, Bartsch U, Stocking C, Fehse B. 2008. A multicolor panel of novel lentiviral 'gene ontology' (LeGO) vectors for functional gene analysis. Mol Ther 16: 698-706.
54. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. 2013. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154: 1370-1379.